Validation of the M. D. Anderson Symptom Inventory multiple myeloma module

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Jones, Desiree ^a   Vichaya, Elisabeth G ^a   Wang, Xin Shelley ^a   Williams, Loretta A ^a   Shah, Nina D ^a   Thomas, Sheeba K ^a   Johnson, Valen E ^a,b   Champlin, Richard E ^a   Cleeland, Charles S ^a   Mendoza, Tito R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Assessment; MDASI; Multiple myeloma; Symptoms; Validation

Indexed keywords

BORTEZOMIB; THALIDOMIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT TOOL; COGNITION; FEMALE; HUMAN; M D ANDERSON SYMPTOM INVENTORY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; RATING SCALE; SENSITIVITY ANALYSIS; STEM CELL TRANSPLANTATION; VALIDATION STUDY;

COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84873248158     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-13     Document Type: Article

References (33)

1. Recent major improvement in long-term survival of younger patients with multiple myeloma. Brenner H, Gondos A, Pulte D, Blood 2008 111 2521 2526 10.1182/blood-2007-08-104984 17901246
2. Strategies to improve the outcome of stem cell transplantation in multiple myeloma. Catley L, Anderson K, The hematology journal: the official journal of the European Haematology Association/EHA 2004 5 9 23 (Pubitemid 38262785)
3. Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. Chapko MK, Syrjala KL, Schilter L, Cummings C, Sullivan KM, Bone Marrow Transplant 1989 4 181 186 2650788 (Pubitemid 19089747)
4. Autologous blood and marrow transplantation in patients 60 years and older. Leger CS, Bredeson C, Kearns B, Bence-Bruckler I, Atkins H, Huebsch L, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 2000 6 204 210 10.1016/S1083-8791(00)70044-9
5. Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Sherman AC, Simonton S, Latif U, Spohn R, Tricot G, Bone Marrow Transplant 2004 33 955 962 10.1038/sj.bmt.1704465 15034542 (Pubitemid 38660130)
6. Measurement of health-related quality of life in multiple myeloma. Nordic myeloma study group. Wisloff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S, Palva I, Westin J, British journal of haematology 1996 92 604 613 10.1046/j.1365-2141.1996.352889.x 8616024 (Pubitemid 26076761)
7. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Cocks K, Cohen D, Wisloff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, European journal of cancer (Oxford, England: 1990) 2007 43 1670 1678 10.1016/j.ejca.2007.04.022 (Pubitemid 47042371)
8. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC, Cancer 2000 89 1634 1646 10.1002/1097-0142(20001001)89:7<1634:: AID-CNCR29>3.0.CO;2-V 11013380
9. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, de la Loge C, Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006 24 976 982 10.1200/JCO.2005.04.0824 (Pubitemid 46638852)
10. Content development for the functional assessment of cancer therapy-multiple myeloma: Use of qualitative and quantitative methods for scale construction. Wagner LI, Robinson D Jr, Weiss M, Katz M, Greipp P, Fonseca R, Cella D, J Pain Symptom Manage 2012 43 1094 1104 10.1016/j.jpainsymman.2011.06. 019 22575718
11. Cancer symptom assessment instruments: a systematic review. Kirkova J, Davis MP, Walsh D, Tiernan E, O'Leary N, LeGrand SB, Lagman RL, Russell KM, Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006 24 1459 1473 10.1200/JCO.2005.02.8332 (Pubitemid 46622014)
12. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Gning I, Trask PC, Mendoza TR, Harle MT, Gutierrez KA, Kitaka SA, Sherman SI, Cleeland CS, Oncology 2009 76 59 68 10.1159/000178809 19052478
13. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). Armstrong TS, Mendoza T, Gning I, Coco C, Cohen MZ, Eriksen L, Hsu MA, Gilbert MR, Cleeland C, Journal of neuro-oncology 2006 80 27 35 10.1007/s11060-006-9135-z 16598415 (Pubitemid 44473259)
14. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Mendoza TR, Wang XS, Lu C, Palos GR, Liao Z, Mobley GM, Kapoor S, Cleeland CS, The oncologist 2011 16 217 227 10.1634/theoncologist.2010-0193 21285393
15. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, Weber RS, Lewin JS, Garden AS, Ang KK, Head Neck 2007 29 923 931 10.1002/hed.20602 17358040
16. The use of cognitive interviewing techniques in quality of life and patient-reported outcomes assessment. Willis GRB, Barofsky I, Outcomes Assessment in Cancer: Measures, Methods, and Applications Cambridge: Cambridge University Press, Lipscomb J, Gotay CC, Snyder C, 2005 610 622
17. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS, Pain 1995 61 277 284 10.1016/0304-3959(94)00178-H 7659438
18. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL, Cancer 1999 85 1186 1196 10.1002/(SICI)1097- 0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N 10091805 (Pubitemid 29115600)
19. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, J Natl Cancer Inst 1993 85 365 376 10.1093/jnci/85.5.365 8433390 (Pubitemid 23073154)
20. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP, Am J Clin Oncol 1982 5 649 655 10.1097/00000421-198212000-00014 7165009 (Pubitemid 13149996)
21. Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Cleeland CS, Gonin R, Baez L, Loehrer P, Pandya KJ, Annals of internal medicine 1997 127 813 816 9382402 (Pubitemid 27465549)
22. Pain and its treatment in outpatients with metastatic cancer. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ, N Engl J Med 1994 330 592 596 10.1056/NEJM199403033300902 7508092 (Pubitemid 24065792)
23. Nunnally J, Bernstein IH, Pscyhometric Theory New York: McGraw-Hill 3 1994
24. Detecting worms, ducks and elephants: A simple approach for defining clinically relevant effects in qualty-of-life measures. Sloan JA, Vargas-Chanes D, Kamath CC, Sargent DJ, Novotny PJ, Atherton P, J Cancer Integr Med 2003 1 1 41 47
25. Cohen J, Statistical Power Analysis for the Behavioral Sciences NJ: Lawrence Earlbaum Associates 2 1988
26. A power primer. Cohen J, Psychol Bull 1992 112 155 159 19565683
27. Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here? Efficace F, Novik A, Vignetti M, Mandelli F, Cleeland CS, Haematologica 2007 92 1596 1598 10.3324/haematol.11710 18055981 (Pubitemid 350248237)
28. Patient reported outcomes as endpoints in medical research. Fairclough DL, Stat Methods Med Res 2004 13 115 138 10.1191/0962280204sm357ra 15068257 (Pubitemid 38379776)
29. Greek M.D. Anderson Symptom Inventory: validation and utility in cancer patients. Mystakidou K, Cleeland C, Tsilika E, Katsouda E, Primikiri A, Parpa E, Vlahos L, Mendoza T, Oncology 2004 67 203 210 10.1159/000081318 15557779 (Pubitemid 39551702)
30. Validation and application of the Arabic version of the M. D. Anderson symptom inventory in Moroccan patients with cancer. Nejmi M, Wang XS, Mendoza TR, Gning I, Cleeland CS, Journal of pain and symptom management 2010 40 75 86 10.1016/j.jpainsymman.2009.12.007 20619213
31. Japanese version of the MD Anderson Symptom Inventory: a validation study. Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y, J Pain Symptom Manage 2003 26 1093 1104 10.1016/j.jpainsymman.2003.05.003 14654261 (Pubitemid 37488017)
32. Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Wang XS, Wang Y, Guo H, Mendoza TR, Hao XS, Cleeland CS, Cancer 2004 101 1890 1901 10.1002/cncr.20448 15386315 (Pubitemid 39314754)
33. Validation study of the Korean version of the M. D. Anderson Symptom Inventory. Yun YH, Mendoza TR, Kang IO, You CH, Roh JW, Lee CG, Lee WS, Lee KS, Bang SM, Park SM, Journal of pain and symptom management 2006 31 345 352 10.1016/j.jpainsymman.2005.07.013 16632082